Samsung Biologics to Participate in Interphex Week Tokyo 2025

Presentation to Showcase ADC CDMO Competitiveness

Samsung Biologics announced on July 8 that it will participate in "Interphex Week Tokyo 2025," a comprehensive bio and pharmaceutical convention to be held in Tokyo, Japan, from July 9 to 11.

Interphex Week Tokyo 2025 is Asia's largest B2B convention organized by the global exhibition company RX (Reed Exhibitions). The event is recognized for its focus on discussions around bio and pharmaceutical manufacturing as well as research and development (R&D) technology partnerships. Now in its 27th year, this event is expected to attract more than 34,000 attendees from 900 companies across 25 countries.

Following last year, Samsung Biologics will once again operate its own independent booth and plans to actively engage in meetings to expand its base of new clients. In particular, the company aims to accelerate the acquisition of new customers among the top 40 global pharmaceutical companies through this event. After opening a sales office in the United States, Samsung Biologics also established a sales office in Tokyo earlier this year, further accelerating its efforts to expand in the Asian market.

On the first day of the event, Mark Studer, head of the ADC/mRNA Operations Team at Samsung Biologics, will deliver a speaking session on the topic "Navigating the Complexity of ADCs: Ensuring Safety, Quality, and Speed through Strategic CDMO Partnerships," highlighting the company's competitive edge in antibody-drug conjugate (ADC) contract development and manufacturing (CDMO) services.

In March of this year, Samsung Biologics began operations at its dedicated ADC manufacturing facility, marking its official entry into the ADC CDMO business. The company has established a 500-liter conjugation reactor and purification line, providing the necessary infrastructure for the production of ADC drug substances (DS). By 2027, Samsung Biologics plans to add drug product (DP) capabilities and offer end-to-end ADC CDMO services.

Meanwhile, Samsung Biologics is strengthening its order intake activities this year by participating in a variety of global events. The company met with a range of clients at the JP Morgan Healthcare Conference in January and at DCAT Week in March, and also showcased its strong order competitiveness at the BIO International Convention held in Boston, United States, last month. Looking ahead, Samsung Biologics plans to further expand its connections with global and potential clients at events such as BioJapan 2025 and CPHI Worldwide in October.